Malaria, primarily caused by Plasmodium falciparum, remains a significant global health concern, with an increase in cases and deaths reported in 2021. Research efforts, including vaccines and monoclonal antibodies, are ongoing to improve prevention and treatment. A monoclonal antibody called L9LS showed promising results in a phase 2 trial in children in Mali, providing up to 70% protection against P falciparum infection and clinical malaria. This approach could complement existing prevention methods, especially in vulnerable populations such as children. The study supports the use of monoclonal antibodies to reduce malaria morbidity and improve coverage in high-risk populations.
Source link
A Monoclonal Antibody Could Help Fight Malaria
